Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

[at noodls] – Data to Be Presented at the Muscular Dystrophy Association Scientific Conference CAMBRIDGE, MA — (Marketwired) — 04/05/13 — Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based … more

View todays social media effects on SRPT

View the latest stocks trending across Twitter. Click to view dashboard

See who Sarepta is hiring next, click here to view